Article Text

This article has a correction. Please see:

other Versions

PDF
Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination
  1. Albert Holvast (b.holvast{at}int.umcg.nl)
  1. University Medical Center Groningen, Netherlands
    1. Coen A. Stegeman (c.a.stegeman{at}int.umcg.nl)
    1. University Medical Center Groningen, Netherlands
      1. Cornelis A. Benne (c.a.benne{at}infectielab.nl)
      1. Laboratory for Infectious Diseases, Netherlands
        1. Anke Huckriede (a.l.w.huckriede{at}med.umcg.nl)
        1. University Medical Center Groningen, Netherlands
          1. Jan C. Wilschut (j.c.wilschut{at}med.umcg.nl)
          1. University Medical Center Groningen, Netherlands
            1. Abraham M. Palache (bram.palache{at}solvay.com)
            1. Solvay Pharmaceuticals, Netherlands
              1. Cees G.M. Kallenberg (c.g.m.kallenberg{at}int.umcg.nl)
              1. University Medical Center Groningen, Netherlands
                1. Marc Bijl (m.bijl{at}int.umcg.nl)
                1. University Medical Center Groningen, Netherlands

                  Abstract

                  Objectives: Wegener’s granulomatosis (WG) is a systemic vasculitis characterized by relapsing and remitting disease activity. Immunosuppressive drugs are used to control disease, but increase susceptibility to infection. Therefore, influenza vaccination should be considered in WG patients. This study was performed to assess immunogenicity of influenza vaccination in WG patients.

                  Methods: We performed a randomized, controlled trial in WG patients with quiescent disease, defined as Birmingham Vasculitis Activity Score (BVAS) < 2. Patients were randomized to receive influenza vaccination (n = 49) or to participate as control (n = 23). In addition, healthy controls (n = 49) were vaccinated. At entry and at one and three to four months after entry, antibody responses to vaccination were determined. Furthermore, disease activity was measured (BVAS), adverse effects were recorded, and antineutrophil cytoplasmic autoantibodies (ANCA) titers were determined.

                  Results: WG patients achieved high seroprotection rates to all three influenza strains, comparable to healthy controls. Only for the A/H1N1 strain patients had a lower seroconversion rate (p = 0.002) and geometric mean titer (p = 0.037) than controls. After one month, one control and one vaccinated WG patient had developed active disease. At three to four months, two additional control patients had developed active disease versus none of the vaccinated patients (p = 0.099). Vaccination did not influence ANCA titers. Adverse effects did not differ between patients and healthy controls.

                  Conclusions: Influenza vaccination in WG patients with quiescent disease induced a sufficient antibody response. Dutch Trial Register, NTR1130.

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                  Linked Articles

                  • Letter
                    BMJ Publishing Group Ltd and European League Against Rheumatism